# Awake versus intubated video-assisted thoracoscopic surgery for pleural disease: a retrospective cohort study from a single tertiary center

**Authors:** Omer Faruk Saglam, Burcu Kilic, Merve Ekinci Fidan, Nevzat Cem Sayilgan, H. Volkan Kara, Akif Turna, Kamil Kaynak, Ezel Ersen

PMC · DOI: 10.3389/fsurg.2025.1635663 · Frontiers in Surgery · 2025-07-17

## TL;DR

This study compares awake and intubated video-assisted thoracoscopic surgery for pleural disease, finding that awake surgery may offer better pain control and recovery.

## Contribution

The study provides new evidence on the feasibility and outcomes of awake VATS as an alternative to intubated VATS in high-risk patients.

## Key findings

- A-VATS showed significantly lower postoperative pain scores and reduced NSAID use compared to I-VATS.
- A-VATS patients experienced earlier oral intake, mobilization, and bowel function recovery.
- Hospital stay was longer for A-VATS, but complication rates and costs were similar between groups.

## Abstract

Awake video-assisted thoracoscopic surgery (A-VATS) has gained increasing attention as an alternative to classical intubated VATS (I-VATS), particularly in patients with comorbidities that have increased the risk of surgery under general anesthesia. This study aimed to compare the perioperative and postoperative outcomes of patients who underwent A-VATS vs. I-VATS for pleural diseases.

This is a retrospective cohort study including patients who underwent A-VATS (n = 22) and I-VATS (n = 37) for pleural diseases between July 2015 and March 2023 at a single tertiary step medical center. Patients considered unsuitable or at high risk for I-VATS due to anesthetic risk or comorbidities were allocated to the A-VATS group. Demographic characteristics, comorbidities, risk scores, spirometry results, surgical outcomes, anesthesia satisfaction, surgical and other complications, and laboratory parameters were analyzed.

A-VATS had significantly lower NRS scores at all postoperative timepoints (1, 12, 48 h; p < 0.01) and reduced NSAID use (p = 0.04), whereas opioid use was similar between the groups. The incidence of postoperative atelectasis was higher in the I-VATS group (p < 0.001). Earlier oral intake, mobilization, and return of bowel function were observed in the A-VATS group (all values compared were p < 0.001). Although the hospital stay was longer in the A-VATS group (5.0 vs. 2.0 days; p = 0.01), there was no difference in hospitalization costs between the groups (p > 0.05). There was no difference in the overall complication rates (p > 0.05). Hematological and biochemical parameter changes were similar between the groups.

A-VATS is a potential feasible alternative in appropriate patients who have a higher risk with I-VATS. A-VATS offers favorable outcomes in terms of postoperative pain control and better recovery so may replace I-VATS. However, its use requires careful patient selection and perioperative planning due to the occurrence of severe complications in some cases. Prospective randomized, patient matched larger and multiple study groups are needed and in our future plan to confirm these findings and optimize the perioperative and postoperative protocols for A-VATS.

## Full-text entities

- **Diseases:** upper airway weakness (MESH:D018908), effusion (MESH:D000080324), pneumothorax (MESH:D011030), infections (MESH:D007239), malignancies (MESH:D009369), Chronic renal failure (MESH:D007676), acute and chronic inflammation (MESH:D007249), hypotension (MESH:D007022), tissue injuries (MESH:D017695), immune dysfunction (MESH:D007154), ASA III (MESH:C000719191), arrhythmia (MESH:D001145), neoplastic diseases (MESH:D004194), metastasis (MESH:D009362), complication (MESH:D008107), ventilator dependence (MESH:D053717), myocardial ischemia (MESH:D017202), cardiovascular diseases (MESH:D002318), tachycardia (MESH:D013610), pain (MESH:D010146), postoperative infections (MESH:D013530), pneumonia (MESH:D011014), bradycardia (MESH:D001919), Surgical trauma (MESH:D007431), Atelectasis (MESH:D001261), Postoperative pain (MESH:D010149), pleural effusion (MESH:D010996), tissue trauma (MESH:D014947), lung cancer (MESH:D008175), bronchospasm (MESH:D001986), airway obstruction (MESH:D000402), cardiac, or diabetes mellitus (MESH:D003920), bleeding (MESH:D006470), hypoxemia (MESH:D000860), psychiatric or neurological disorders (MESH:D001523), respiratory complications (MESH:D012140), hypertension (MESH:D006973), muscle blockade (MESH:D020879), hypoxic (MESH:D002534), sore throat (MESH:D010612), flatulence (MESH:D005414), hypercapnic (MESH:D012131), pleural disease (MESH:D010995), sinus tachycardia (MESH:D013616), lung and diaphragmatic dysfunction (MESH:D008171), air leak (MESH:D004618)
- **Chemicals:** propofol (MESH:D015742), dexamethasone (MESH:D003907), epinephrine (MESH:D004837), morphine (MESH:D009020), midazolam (MESH:D008874), I (MESH:D007455), bupivacaine (MESH:D002045), remifentanil (MESH:D000077208), ASA (-), oxygen (MESH:D010100), dexmedetomidine (MESH:D020927), fentanyl (MESH:D005283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310580/full.md

## References

67 references — full list in the complete paper: https://tomesphere.com/paper/PMC12310580/full.md

---
Source: https://tomesphere.com/paper/PMC12310580